Janux Therapeutics
JANX
54 hedge funds and large institutions have $362M invested in Janux Therapeutics in 2023 Q2 according to their latest regulatory filings, with 11 funds opening new positions, 18 increasing their positions, 14 reducing their positions, and 5 closing their positions.
1,082% more call options, than puts
Call options by funds: $201K | Put options by funds: $17K
120% more first-time investments, than exits
New positions opened: 11 | Existing positions closed: 5
29% more repeat investments, than reductions
Existing positions increased: 18 | Existing positions reduced: 14
13% more funds holding
Funds holding: 48 → 54 (+6)
0.08% less ownership
Funds ownership: 73.01% → 72.94% (-0.08%)
2% less capital invested
Capital invested by funds: $370M → $362M (-$7.41M)
Top Buyers
| 1 |
BI
BVF Inc
San Francisco,
California
|
+$33.7M |
| 2 |
Citadel Advisors
Miami,
Florida
|
+$3.51M |
| 3 |
Janus Henderson Group
London,
United Kingdom
|
+$3.21M |
| 4 |
Millennium Management
New York
|
+$1.39M |
| 5 |
Cerity Partners
New York
|
+$814K |
Top Sellers
JANX Hedge Fund Activity: Q2 2023 in Review
54 of the 6,369 institutional investors tracked by Wall St. Rank reported a position in Janux Therapeutics (JANX) for Q2 2023, worth a combined $362M — down 2% from $370M a quarter earlier.
Buyers outnumbered sellers: 11 funds opened new JANX positions and 5 closed out — a net gain of 6 holders — while 18 added to existing stakes and 14 trimmed.
The largest buyer was BVF Inc, adding an estimated $33.7M. The largest seller was EcoR1 Capital, cutting an estimated $45.3M.
- 54 institutional investors held Janux Therapeutics (JANX) as of Q2 2023, up from 48 in Q1 2023.
- Funds reported $362M of Janux Therapeutics stock for Q2 2023, down 2% quarter-over-quarter.
- 11 funds opened new Janux Therapeutics positions in Q2 2023 and 5 closed out, a net change of +6 holders.
- The largest Janux Therapeutics buyer in Q2 2023 was BVF Inc, an estimated $33.7M added.
- The largest Janux Therapeutics seller in Q2 2023 was EcoR1 Capital, an estimated $45.3M sold.
Based on aggregated 13F filings for Q2 2023.